Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020
Lutz Naehrlich, Annalisa Orenti, Fiona Dunlevy, et al.
Journal of Cystic Fibrosis (2021) Vol. 20, Iss. 4, pp. 566-577
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases
Eusebi Chiner‐Vives, Rosa Cordovilla, David de la Rosa, et al.
Archivos de Bronconeumología (2022) Vol. 58, pp. 39-50
Open Access | Times Cited: 52
SARS-CoV-2 viral entry and replication is impaired in Cystic Fibrosis airways due to ACE2 downregulation
Valentino Bezzerri, Valentina Gentili, Martina Api, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 28
Standards for the care of people with cystic fibrosis (CF); Planning for a longer life
Andrea Gramegna, C. Addy, Lorna Allen, et al.
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 3, pp. 375-387
Closed Access | Times Cited: 7
Success of the German Cystic Fibrosis Registry
Lutz Naehrlich, Manuel Burkhart
Pharmacoepidemiology and Drug Safety (2025) Vol. 34, Iss. 1
Open Access
Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study
S.B. Carr, Elliot McClenaghan, Alexander Elbert, et al.
Journal of Cystic Fibrosis (2022) Vol. 21, Iss. 4, pp. e221-e231
Open Access | Times Cited: 19
Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe
Andreas Jung, Annalisa Orenti, Fiona Dunlevy, et al.
ERJ Open Research (2021) Vol. 7, Iss. 4, pp. 00411-2021
Open Access | Times Cited: 24
Clinical course and risk factors for severe COVID-19 among Italian patients with cystic fibrosis: a study within the Italian Cystic Fibrosis Society
Carla Colombo, Marco Cipolli, Valeria Daccò, et al.
Infection (2021) Vol. 50, Iss. 3, pp. 671-679
Open Access | Times Cited: 24
Risk factors for severe COVID-19 in people with cystic fibrosis: A systematic review
Vito Terlizzi, Marco Antonio Motisi, Roberta Pellegrino, et al.
Frontiers in Pediatrics (2022) Vol. 10
Open Access | Times Cited: 16
COVID-19 outcomes in people with cystic fibrosis
Pierre‐Régis Burgel, Christopher H. Goss
Current Opinion in Pulmonary Medicine (2021) Vol. 27, Iss. 6, pp. 538-543
Open Access | Times Cited: 20
The inflammatory microenvironment of the lung at the time of infection governs innate control of SARS-CoV-2 replication
Paul J. Baker, Andrea C. Bohrer, Ehydel Castro, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York
Joseph L. Simonson, Christine Tanaka Esposito, T. Frantzen, et al.
Journal of Cystic Fibrosis (2022) Vol. 21, Iss. 3, pp. e176-e183
Open Access | Times Cited: 11
Cumulative Incidence and Risk Factors for Severe Coronavirus Disease 2019 in French People With Cystic Fibrosis
Harriet Corvol, Sandra de Miranda, Clémence Dehillotte, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 12, pp. 2135-2144
Open Access | Times Cited: 11
TGF-β1 Inhibition of ACE2 Mediated by miRNA Uncovers Novel Mechanism of SARS-CoV-2 Pathogenesis
Ewelina D. Hejenkowska, Nilay Mitash, J. Donovan, et al.
Journal of Innate Immunity (2023) Vol. 15, Iss. 1, pp. 629-646
Open Access | Times Cited: 5
The impact of SARS-CoV-2 infection in patients with cystic fibrosis undergoing CFTR channel modulators treatment: a literature review
Antonio Vitiello, Michela Sabbatucci, Andrea Silenzi, et al.
Respiratory Research (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 5
The Impact of COVID-19 in Cystic Fibrosis
Patrick A. Flume, Lisa Saiman, Bruce C. Marshall
Archivos de Bronconeumología (2021) Vol. 58, Iss. 6, pp. 466-468
Open Access | Times Cited: 13
Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement
Marcello Lanari, Elisabetta Venturini, Luca Pierantoni, et al.
˜The œItalian Journal of Pediatrics/Italian journal of pediatrics (2022) Vol. 48, Iss. 1
Open Access | Times Cited: 9
A feasibility study investigating the use of a thigh-worn accelerometer to measure physical activity in patients recovering from critical illness
Laura Jones
Deleted Journal (2024) Vol. 56, Iss. 1, pp. 3-8
Open Access | Times Cited: 1
The challenge of defining ‘safe staffing’ for physiotherapists in critical care
Rebekah Haylett
Deleted Journal (2024) Vol. 56, Iss. 1, pp. 55-57
Open Access | Times Cited: 1
Exploring physiotherapists’ experiences in delivering care remotely to adults with Cystic Fibrosis during the COVID-19 pandemic in the United Kingdom
Angeliki Vasilopoulou
Deleted Journal (2024) Vol. 56, Iss. 1, pp. 20-28
Open Access | Times Cited: 1
Simulation-based education within respiratory physiotherapy training: a scoping review
Stephanie K Mansell
Deleted Journal (2024) Vol. 56, Iss. 1, pp. 37-51
Open Access | Times Cited: 1
Epidemiological Profile of Hospitalized Patients with Cystic Fibrosis in Brazil Due to Severe Acute Respiratory Infection during the COVID-19 Pandemic and a Systematic Review of Worldwide COVID-19 in Those with Cystic Fibrosis
Leonardo Souza Marques, Matheus Negri Boschiero, Nathália Mariana Santos Sansone, et al.
Healthcare (2023) Vol. 11, Iss. 13, pp. 1936-1936
Open Access | Times Cited: 4
Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS‐CoV‐2 infection and COVID‐19 disease severity
Philip R. Tedbury, Candela Manfredi, Frauke Degenhardt, et al.
The FASEB Journal (2023) Vol. 37, Iss. 11
Closed Access | Times Cited: 4
Beyond Borders of the Cell: How Extracellular Vesicles Shape COVID-19 for People with Cystic Fibrosis
Ewelina D. Hejenkowska, Hayrettin Yavuz, Agnieszka Swiatecka‐Urban
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3713-3713
Open Access | Times Cited: 1
Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study
Julie Semenchuk, Yumi Naito, Susan C. Charman, et al.
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 5, pp. 815-822
Open Access | Times Cited: 1
Stem cells, cell therapies, and bioengineering in lung biology and disease 2021
Laertis Ikonomou, Mattias Magnusson, Ruben Dries, et al.
AJP Lung Cellular and Molecular Physiology (2022) Vol. 323, Iss. 3, pp. L341-L354
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top